About the Opioid Settlements
The state of Texas has participated in settlement agreements with different companies to resolve legal claims against them for their role in the opioid crisis. The companies include opioid marketing consultant McKinsey, pharmaceutical companies Endo and Teva, opioid manufacturer Johnson & Johnson ("Janssen") and pharmaceutical distributors AmerisourceBergen, Cardinal Health and McKesson. The amount of funding Texas anticipates receiving is dependent on the number of local governments that join the settlement agreements.
As of early 2023, some opioid related litigation is ongoing. The Office of the Attorney General is working with political subdivisions to sign on to additional settlement proceedings. For information regarding ongoing opioid litigation, contact the Office of the Attorney General.
Opioid Settlements at a Glance
Of the total amounts received from statewide opioid settlement agreements, 15 percent is deposited to the Opioid Abatement Account and 85 percent is deposited to the Opioid Abatement Trust Fund (Trust Fund) held at the Texas Treasury Safekeeping Trust Company (TTSTC). The Trust Fund is held at the TTSTC outside of the state treasury.
The Opioid Abatement Account is an account in general revenue consisting primarily of amounts from statewide opioid settlement agreements. Funds in the account may be appropriated through the legislative process only to a state agency to address opioid-related prevention, treatment programs and as otherwise permitted by statute or appropriation.
Of the total settlement amounts:
- 15 percent is distributed through the Trust Fund to counties and municipalities to address opioid-related harms in those communities.
- $5 million from the Trust Fund is distributed to the Texas Access to Justice Foundation for providing basic civil legal services to indigent persons and children directly impacted by opioid-use disorders.
- The remainder of the amount deposited to the Trust Fund is allocated to the Texas Opioid Abatement Fund Council. One percent of the Council’s allocation is distributed to the Comptroller’s office for administration and 15 percent is disbursed to hospital districts. The remaining amount is distributed through the opioid abatement strategy developed by the Council for regional allocations (PDF) and targeted interventions.
Settlement Agreement and Related Documents
- CVS Settlement Agreement dated Dec. 9, 2022 (PDF)
- Walgreens Settlement Agreement dated Dec. 9, 2022 (PDF)
- Allergan Settlement Agreement dated Nov. 22, 2022 (PDF)
- Walmart Settlement Agreement dated Nov. 14, 2022 (PDF)
- Texas Distributors Settlement Agreement dated Feb. 7, 2022 (PDF)
- Teva TX State-Wide Opioid Settlement dated Feb. 4, 2022 (PDF)
- Janssen State-Wide Settlement Agreement and Term Sheet as of Oct. 14, 2021 (PDF)
- Janssen Global Settlement Term Sheet dated July 21, 2021 (PDF)
- Distributors (AmerisourceBergen, Cardinal Health and McKesson) Global Settlement Agreement dated July 21, 2021 (PDF)
- McKinsey Agreed Final Judgment and Permanent Injunction dated Feb. 4, 2021 (PDF)
- Endo TX Settlement Term Sheet dated Dec. 23, 2021 (PDF)
- Global Settlement Allocation Term Sheet dated May 13, 2020 (PDF)